• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Aug 29, 2024 | Press Releases

Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDTMarlborough, Massachusetts–(Newsfile Corp. – August 29, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – August 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more...

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio’s Patented INTASYL Compound

Aug 6, 2024 | Press Releases

Phio’s INTASYL compound targets aging skin disordersMarlborough, Massachusetts–(Newsfile Corp. – August 6, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene...

Phio Pharmaceuticals Announces New Chief Financial Officer

Aug 1, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – August 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more...

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 12, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – July 12, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the “Company”), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to...

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 8, 2024 | Press Releases

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts–(Newsfile Corp. – July 8, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL®...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
  • Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
  • Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2026 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us